An observational study in Sudden Sensorineural Hearing Loss (SSNHL) and Hyperbaric Oxygen Therapy, sponsored by Sun Yuting. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Sun Yuting · Observational
Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.
Among the 18 studies in Hearing Loss, Sudden with a site in China, this one is one of 3 that started in 2025, is one of 3 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 11th registered.
66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.
This study's planned enrollment of 1,309 is above the median of 82 across 14 observational studies indexed under Hearing Loss, Sudden.
Browse Hearing Loss, Sudden studies →11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now, in 1 country. Each count lists the studies.
Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; 0 take children under 18; 0 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →18 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 3 started in 2025.
Median enrollment 90 across the 15 interventional studies, 90 across the 3 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
1 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sun Yuting as lead sponsor.
Sun Yuting has 1 study filed under Hearing Loss, Sudden — fewer than ten, so there is no comparison to draw.
2 of the studies in Hearing Loss, Sudden with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07134075Eye & ENT Hospital of Fudan UniversityIntracochlear Injection of Glucocorticoid | 2027-08-01 |
| NCT07505667Guangdong Provincial People's HospitalYiyuancong for the Treatment of Sudden Sensorineural Hearing Loss | 2027-11-15 |
Among the 18 studies in Hearing Loss, Sudden with a site in China, from their registry updates:
The objective of this observational study was to understand the effect of HBO on patients with SSNHL and its association with coagulation function and prognosis.
The main question it aims to answer is whether HBO therapy can improve outcomes and coagulation function in patients with SSNHL.
The prognosis of SSNHL patients receiving HBO and SSNHL patients not receiving HBO were compared
From January 2022 to September 2024, in Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Otolaryngology Hospital Affiliated to Fudan University, Xinhua Hospital affiliated to Shanghai Jiao Tong University or Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, treating patients with sudden sensorineural deafness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
HBO therapy is the process of inhaling 100% pure oxygen in an environment above one atmosphere (pressure range: 2.0-3.0 absolute atmospheres) to treat a disease.
Hearing recovery rate
The rate of hearing recovery in patients with all levels of hearing loss at completion of treatment and at 3 months after termination of treatment was assessed according to the WHO Hearing Loss Rating Criteria 2021 to determine the success of treatment.
Time frame: From onset to 3 months after treatment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2025; primary completion for Jun 2025, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.